Abstracts tagged "COVID-19"

Abstract Number: 1201 • ACR Convergence 2024
Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Minerva Nong¹, Colby Lewis V², Genna Braverman³, Vivian Bykerk³, Nathaniel Hupert², Medha Barbhaiya³ and Lisa Mandl³, ¹Hospital for Special Surgery, Tampa, FL, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
Abstract Number: 2182 • ACR Convergence 2024
PECOS (Pediatric SARS-CoV-2 MIS-C Long-term Outcomes Study): Preliminary Results
Gina Montealegre Sanchez¹, Lauren Arrigoni², Kevin Rubenstein³, Max Wolff⁴, Mallory Barrix², C. Jason Liang⁵, James Bost⁶, Meghan Delaney⁷, Luigi Notarangelo⁸, Karyl Barron⁹ and Roberta DeBiasi¹⁰, and PECOS Study Team, ¹Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID),National Institutes of Health (NIH), Bethesda, MD, ²Center for Cancer and Immunology Research (CCIR), Children's National Research Institute, Washington, DC, ³Clinical Monitoring Research Program Directorate (CMRPD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, ⁴Clinical Research Directorate (CRD), National Cancer Institute Frederick National Laboratory for Cancer Research, Frederick, MD, ⁵Biostatistics Research Branch, NIAID, NIH, Bethesda, MD, ⁶Division of Biostatistics and Study Methodology and Center for Translational Research, Children's National Research Institute, Washington, DC, ⁷Department of Pathology and Laboratory Medicine, Children's National Hospital, Washington, DC, ⁸Laboratory of Clinical Immunology and Microbiology (LCIM), NIAID, Bethesda, MD, ⁹Division of Clinical Research (DCR), National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, ¹⁰Children's National Hospital and Research Institute, Washington, DC
Background/Purpose: The long-term sequelae of SARS-CoV-2 infection in children are unknown. PECOS is a large prospective observational cohort study with the main objective to characterize…
Abstract Number: 0241 • ACR Convergence 2024
Anti-Spike Antibodies in SARS-CoV-2-Vaccinated SLE Patients
Rebecca Sadun¹, Dan Crair¹, Emmanuel Walter¹, Eugene St.Clair², David Pisetsky², Amanda Eudy³, Megan Clowse⁴, Jennifer Rogers⁵, Kai Sun¹, Lisa Criscione-Schreiber⁶, Mithu Maheswaranathan⁶, Jayanth Doss¹, Sarah Valencia¹ and M. Athony Moody⁷, ¹Duke University, Durham, NC, ²Duke University Medical Center, Durham, NC, ³Duke University, Raleigh, NC, ⁴Duke University, Chapel Hill, NC, ⁵Duke, Durham, NC, ⁶Duke University School of Medicine, Durham, NC, ⁷Duke University School of Medicine, Durham
Background/Purpose: The ACR recommends SARS-CoV-2 vaccination for all patients with rheumatic diseases, but it is unknown how patients with SLE will respond to the vaccine,…
Abstract Number: 1249 • ACR Convergence 2024
Patient-Reported Outcomes in Inflammatory Arthritis: A Four-Year Retrospective Analysis via the PatientSpot Research Registry
Shilpa Venkatachalam¹, Kelly Gavigan², Erik Stone³, Angela Degrassi², Laura Stradford⁴, David Curtis², Esteban Rivera⁵ and Jeffrey Curtis⁶, ¹Global Healthy Living Foundation, New York, NY, ²Global Healthy Living Foundation, Upper Nyack, NY, ³Global Healthy Living Foundation, Upper Nyack, ⁴Global Healthy Living Foundation, Nyack, NY, ⁵Global Healthy Living Foundation, Long Island City, NY, ⁶University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Understanding the impact of inflammatory arthritis from patients’ perspectives through patient-reported outcomes (PROs) data can provide valuable insights into outcomes prioritized by those living…
Abstract Number: 2198 • ACR Convergence 2024
Severe and Long-Term Outcomes of COVID-19 Infection and Vaccine Hesitancy and Adverse Events in Children with Pediatric Rheumatic Diseases: Insights from a COVID-19 Global Rheumatology Alliance Caregiver Survey
Jonathan Hausmann¹, Kevin Kennedy², Ethan Knapp³, Nadine Lalonde⁴, jOhn Wallace⁵, Richard Howard⁶, Marcela Alvarez⁷, Mariana Fabi⁸, Lorena Franco⁹, Rebecca Grainger¹⁰, Jean Liew¹¹, Pedro M Machado¹², Zachary Wallace¹³, Jinoos Yazdany¹⁴ and Emily Sirotich¹⁵, and COVID-19 Global Rheumatology Alliance, ¹Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, ²McMaster University, Hamilton, ON, Canada, ³University of Connecticut School of Medicine, Farmington, CT, ⁴COVID-19 Global Rheumatology Alliance, London, ON, Canada, ⁵Covid 19 Global Rheumatology Alliance Patient Board, EDINBURGH, United Kingdom, ⁶Spondylitis Association of America, Encino, CA, ⁷CHIDRENS HOSPITAL DR. RICARDO GUTIERREZ ARGENTINA, Buenos Aires, Argentina, ⁸Argentine Society of Rheumatology, La Plata, Argentina, ⁹Argentine Society of Rheumatology, Cordoba, Argentina, ¹⁰University of Otago, Wellington, New Zealand, ¹¹Boston University, Boston, MA, ¹²Department of Neuromuscular Diseases and Centre for Rheumatology, University College London, London, United Kingdom, ¹³Massachusetts General Hospital, Newton, MA, ¹⁴UCSF, San Francisco, CA, ¹⁵Yale University, Vaughan, ON, Canada
Background/Purpose: Children have the lowest COVID-19 vaccination rates of any age group. In adults with rheumatic diseases, barriers to vaccination include the perceived lack of…
Abstract Number: 0242 • ACR Convergence 2024
Use of Outpatient Antiviral Therapy and Severe Outcomes from SARS-CoV-2 Omicron Infection in Patients with Immune Mediated Diseases on B Cell Depleting Agents
Cassandra Calabrese¹, Xiaofang wang², Abhijit Duggal², Gretchen Sacha², Shuaiqi Huang² and Leonard Calabrese², ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Immunocompromised patients constitute a high-risk group for severe COVID-19 outcomes and those on B cell depleting therapy (BCTD) are among the most vulnerable. Previous…
Abstract Number: 1531 • ACR Convergence 2024
Prospective mRNA SARS-CoV-2 Additional Vaccination in Systemic Autoimmune Disease Patients on Immunosuppressive Medications in a Randomized Controlled Trial
Meggan Mackay¹, Catriona Wagner², Ashley Pinckney³, Jeffrey Cohen⁴, Zachary Wallace⁵, Arezou Khosroshahi⁶, Jeffrey Sparks⁷, Sandra Lord⁸, Amit Saxena⁹, Roberto Caricchio¹⁰, Alfred Kim¹¹, Diane Kamen¹², Fotios Koumpouras¹³, Anca Askanase¹⁴, Kenneth Smith¹⁵, Joel Guthridge¹⁵, Susan Macwana¹⁶, Sean McCarthy¹⁷, Matthew Sherman¹⁸, Sanaz Daneshfar Hamrah¹⁹, Maria Veri¹⁹, Kate York²⁰, Sarah Walker²¹, Sandeep Narpala²², Robin Carroll²², Bob Lin²², Leonid Serebryanny²², Adrian McDermott²³, William Barry²¹, Ellen Goldmuntz²⁴, James McNamara²⁵, Sara Tedeschi²⁶, Amit Bar-Or²⁷, Dinesh Khanna²⁸, ACV01 Clinical Study Team¹⁵ and Judith James¹⁵, ¹Feinstein Institutes for Medical Research, Manhasset, NY, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Rho, St Louis Park, NC, ⁴Neurologic Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH, ⁵Massachusetts General Hospital, Newton, MA, ⁶Emory University, Atlanta, GA, ⁷Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ⁸Center for Interventional Immunology, Benaroya Research Institute, Seattle, WA., Seattle, WA, ⁹NYU School of Medicine, New York, NY, ¹⁰University of Massachusetts Chan Medical School, Worcester, MA, ¹¹Washington University School of Medicine, Division of Rheumatology, Department of Medicine, St Louis, MO, ¹²Medical University of South Carolina, Charleston, SC, ¹³Yale School of Medicine, New Haven, CT, ¹⁴Columbia University Medical Center, New York, NY, ¹⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ¹⁶Oklahoma Medical Research Foundation, Oklahoma City, ¹⁷DAIT/NIAID/NIH, Rockville, MD, ¹⁸DAIT/NIAID/NIH, Washington, DC, ¹⁹Division of Allergy, Immunology, and Transplantation, NIH/NIAID, Bethesda, MD, USA., Bethesda, MD, ²⁰Rho Federal Systems Division, Durham, NC, USA., Durham, NC, ²¹Rho, Durham, NC, ²²Vaccine Research Center, NIH/NIAID, Bethesda, MD, USA, Bethesda, MD, ²³Vaccine Research Center, NIH/NIAID, Bethesda, MD, ²⁴NIAID/ NIH, Washington, DC, ²⁵NIH, Bethesda, MD, ²⁶Brigham and Women's Hospital, Boston, MA, ²⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA, Philadelphia, PA, ²⁸Division of Rheumatology, Department of Internal Medicine, University of Michigan, Ann Arbor, Michigan, USA, Ann Arbor, MI
Background/Purpose: Autoimmune disease patients treated with mycophenolate mofetil/mycophenolic acid (MMF/MPA), methotrexate (MTX), or B cell-depleting therapies (BCDT) exhibit reduced humoral responses following primary two-dose COVID-19…
Abstract Number: 2242 • ACR Convergence 2024
A Cross-sectional Study on Predictors of COVID-19 Infection, Admission and Mortality and Effect of Immunomodulating Treatments in Rheumatoid Arthritis
Mohammad Movahedi¹, Elliot Hepworth², Angela Cesta³, Xiuying Li³, Claire Bombardier⁴ and Sibel Aydin⁵, and OBRI investogators, ¹Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ²University of Ottawa, Ottawa, ON, Canada, ³UHN, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Ottawa Hospital Research Institute, Ottawa, ON, Canada
Background/Purpose: COVID-19 infection frequently leads to a cytokine storm, which has successfully been treated with some immunomodulating therapies according to observational studies. Interestingly, treatments investigated…
Abstract Number: 0243 • ACR Convergence 2024
Humoral Response to SARS-CoV-2 Vaccination and Breakthrough COVID-19 Disease in Patients with Immune-mediated Inflammatory Diseases Receiving Biological Treatment
Eve-Kai Raussi, Maigi Eisen, Küllike Palk and Marge Kütt, North Estonia Medical Centre Foundation, Tallinn, Estonia
Background/Purpose: Immune response in patients with immune-mediated inflammatory diseases (IMID) is compromised. As SARS-CoV-2 vaccine trials excluded patients on immunosuppressive therapy, data about vaccination efficacy…
Abstract Number: 1718 • ACR Convergence 2024
Randomization to Holding versus Continuing (JAKi, IL17) and Autoimmune Patient Responses to COVID-19 Boosters: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study
Amy Mudano¹, Gary Cutter², Emily Holladay³, Kevin Winthrop⁴, Ted Mikuls⁵, Geoffrey Thiele⁵, Mark Law⁵, Monique Bastidas⁶, Mike Zikry⁶, Kelly Chun⁶, Michael George⁷, Jayashree Sinha⁸, Naiara Alvarez⁹, John Tesser¹⁰ and Jeffrey Curtis¹¹, and COVER Site Principal Investigator Group, ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³University of Alabama at Birmingham, Edmond, OK, ⁴School of Medicine, Oregon Health and Science University, Portland, OR, ⁵University of Nebraska Medical Center, Omaha, NE, ⁶Labcorp, Calabasas, CA, ⁷University of Pennsylvania, Philadelphia, PA, ⁸self employed, Clovis, NM, ⁹Integrative Rheumatology of South Texas, McAllen, TX, ¹⁰Arizona Arthritis & Rheumatology Associates, Phoenix, AZ, ¹¹University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Best practice for the use of immunosuppression to optimize vaccine response remains uncertain. We conducted the Covid VaccinE Response (COVER) trial, a multicenter, randomized…
Abstract Number: 2613 • ACR Convergence 2024
Vaccination Is Associated with Lower Risk of Parenchymal Lung Disease in Patients with Rheumatoid Arthritis After COVID-19: Results from a Prospective Study
Gregory McDermott¹, Ritu Gill², Suzanne Byrne³, Staci Gagne³, Emily Kowalski³, Xiaosong Wang⁴, Grace Qian⁴, Katarina Bade³, Kevin Mueller³, Alene Saavedra³, Kathleen Vanni⁴, Caleb Bolden⁵, Naomi Patel⁵, Krishan Guzzo³, Marcy Bolster⁵, Shruthi Srivatsan⁵, Pierre-Antoine Juge⁶, Tracy J Doyle⁷, Zachary Wallace⁸ and Jeffrey Sparks⁹, ¹Brigham and Women's Hospital, Brookline, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴Brigham and Women’s Hospital, Boston, MA, ⁵Massachusetts General Hospital, Boston, MA, ⁶Departement of Rheumatology, AP-HP, Bichat Hospital, Boston, MA, ⁷Brigham and Women's Hospital, West Roxbury, MA, ⁸Massachusetts General Hospital, Newton, MA, ⁹Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: RA is associated with several forms of parenchymal lung disease, including interstitial lung disease (ILD), bronchiectasis, and emphysema. Acute COVID-19 and other respiratory viruses…
Abstract Number: 0244 • ACR Convergence 2024
Adjunctive Belimumab Exerts Favorable Ferritin Recovery and Survival for Post-COVID Interstitial Lung Disease in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab: A Case Series
Pei-Hsinq Lai¹, Cheng-Hsun Lu² and Song-Chou Hsieh³, ¹Taipei City Hospital, Taipei, Taiwan (Republic of China), ²National Taiwan University Hospital, Taipei, Taiwan, ³National Taiwan University Hospital, Taipei, Taiwan (Republic of China)
Background/Purpose: Post-COVID interstitial lung disease (post-COVID ILD) is a critical sequelae yet the role of immunomodulatory therapies remains unclear. We explored to characterize post-COVID ILD…
Abstract Number: 1727 • ACR Convergence 2024
Duration of SARS-CoV-2 Viral Shedding After Infection Among Patients with Rheumatic Disease Using Tumor Necrosis Factor Inhibitors or Rituximab
Zachary Wallace¹, Li Yijia², Manish Choudhary², Julie Boucau³, Anusha Nathan³, May Yee Liew³, Gregory Edelstein², Owen Glover³, Yumeko Kawano², Rockib Uddin³, Rinki Deo², Caitlin Marino³, Matthew Getz³, Zahra Reynolds⁴, karry Su⁴, Eliza Passell⁴, Mamadou Barry⁴, Rebecca Gilbert⁴, Dessie Tien⁴, Shruti Sagar⁴, Tammy Vyas⁴, Sarah Hammond², Jatin Vyas⁴, Gaurav Gaiha⁴, Jacob Lemieux⁴, Mark Siedner⁴, Jonathan Li², Amy Barczak⁴ and Jeffrey Sparks⁵, ¹Massachusetts General Hospital, Newton, MA, ²Brigham and Women's Hospital, Boston, MA, ³Ragon Institute of MGH, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: Individuals with rheumatic disease receiving certain immunosuppressive agents are at risk for severe COVID-19. However, it is unclear if rheumatic disease treatments affect the…
Abstract Number: 2614 • ACR Convergence 2024
Risk of New Onset of Immune-Mediated Diseases After Sars-Cov-2 Infection: A Systematic Review and Meta-Analysis
Ana Milena Gil¹, Julián Barahona-Correa², Jorge Bruce Flórez-Suárez³, Daniel Fernández-Ávila⁴ and Zulma Cucunubá¹, ¹Department of Clinical Epidemiology and Biostatistics, Pontificia Universidad Javeriana, Bogotá, Colombia, ²Division of Rheumatology, Pontificia Universidad Javeriana - Hospital Universitario San Ignacio, Bogotá, Colombia, ³Department of Immunology, Universidad Nacional de Colombia, Bogotá, Colombia, ⁴5Hospital San Ignacio, Colombia, BOGOTA, Colombia
Background/Purpose: The association between SARS-CoV-2 infection and the new onset of immune-mediated diseases is a topic of interest given the conflicting evidence available. This systematic…
Abstract Number: 0245 • ACR Convergence 2024
The Impact of COVID-19 and ‘Long COVID’ on Self-Reported Disease Activity, Disability, and Quality of Life in Patients with Inflammatory Arthritis
Zachary Wallace¹, Miao Lin², Shruthi Srivatsan², Andrew King², Xiaosong Wang³, Rathnam Venkat⁴, Naomi Patel², Yumeko Kawano⁵, Abigail Schiff⁵, Jennifer Hanberg², Emily Kowalski⁵, Colebrook Johnson², Kathleen Vanni³, Zachary Williams², Grace Qian³, Caleb Bolden², Kevin Mueller⁵, Katarina Bade⁵, Alene Saavedra⁵ and Jeffrey Sparks⁶, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital, Boston, MA, ³Brigham and Women’s Hospital, Boston, MA, ⁴Tufts University School of Medicine, Boston, MA, ⁵Brigham and Women's Hospital, Boston, MA, ⁶Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA
Background/Purpose: People with rheumatoid arthritis (RA), psoriatic arthritis (PsA), juvenile idiopathic arthritis (JIA), and axial spondyloarthritis (axSpA) are at risk for poor COVID-19 outcomes, including…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].